Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.64 +0.07 (+0.40%)

Delayed Quote Updated: 3:41 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer ↗

June 06, 2022

This biotech stock launched in February to work on CAR-T treatments.

Via Investor's Business Daily

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

June 04, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

June 03, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

June 01, 2022

From Legend Biotech

Via Business Wire

Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2022

From Legend Biotech

Via Business Wire

Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal ↗

May 28, 2022

Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...

Via Talk Markets

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review ↗

May 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

May 26, 2022

From Legend Biotech

Via Business Wire

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA

May 18, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

May 09, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conferences

May 06, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Announces Appointment of Global Head of Research and Early Development

April 01, 2022

From Legend Biotech Corporation

Via Business Wire

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework ↗

April 01, 2022

Via Benzinga

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy ↗

March 25, 2022

The European Medicines Agency's CHMP

Via Benzinga

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

March 25, 2022

From Legend Biotech

Via Business Wire

HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗

May 05, 2022

The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.

Via InvestorPlace

Flanders Investment and Trade Names Legend Biotech Newcomer of the Year

March 23, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

March 18, 2022

From Legend Biotech

Via Business Wire

Analyst Ratings For Legend Biotech ↗

March 15, 2022

Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 14, 2022

Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....

Via Benzinga

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi ↗

March 05, 2022

Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in...

Via Talk Markets

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment ↗

March 01, 2022

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy ↗

March 01, 2022

The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...

Via Talk Markets

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Week In Review: AffaMed Announced US Approval To Start Clinical Trials ↗

February 19, 2022

AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma. On Saturday, AffaMed announced US approval to...

Via Talk Markets

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

February 18, 2022

From Legend Biotech

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.